

2008 BCSECCOM 456

Headnote

Issuer designated a reporting issuer in British Columbia

Designation Order

Sonus Pharmaceuticals, Inc.

Section 3.2(1) of the *Securities Act*, R.S.B.C. 1996, c. 418

Background

- ¶ 1 Sonus Pharmaceuticals, Inc. (Sonus) has applied to be designated as a reporting issuer under the Act.

Representations

- ¶ 2 Sonus represents that:
1. it is incorporated under the laws of the State of Delaware, has been a reporting issuer under section 12(g) of the *United States Securities and Exchange Act* of 1934 (the 1934 Act) since October 15, 1995, and is not in default of the requirements under section 12(g) of the 1934 Act;
 2. its authorized capital consists of 75,000,000 shares of common stock with a par value of \$0.001 per share and 5,000,000 shares of preferred stock with a par value of \$0.001, of which 37,089,679 shares of common stock and nil shares of preferred stock were outstanding as of August 11, 2008;
 3. its common shares are currently listed and posted for trading on the NASDAQ Global Market, but are likely to trade in the future on the NASDAQ Capital Market or the NASD Over-the-Counter Bulletin Board.

Order

- ¶ 3 Considering that it is not prejudicial to the public interest, the Commission orders under section 3.2(1) of the Act that Sonus is designated as a reporting issuer under the Act.
- ¶ 4 August 13, 2008

Martin Eady, CA
Director, Corporate Finance
British Columbia Securities Commission